"The next decade of radiation oncology will not be won inside the vault. It will be won by the practices that learn to treat cancer the body cannot localize."
Field note from a multi-site theranostics build
Why radiation oncology wins the RPT race.
Nuclear medicine and medical oncology are both eyeing the radiopharmaceutical market, but radiation oncology practices hold the strategic high ground. You already own the infrastructure that everyone else has to build from scratch.
Shielding and safety
Your facility is already designed to handle ionizing radiation. Adding a hot lab is a minor adjustment compared to a medical oncology office trying to retrofit for radiation safety.
Specialized physics
You already employ the medical physicists and dosimetrists required to manage complex isotope calculations. That bench of expertise is a real barrier to entry for competitors.
Workflow maturity
Managing toxicities, radiation decay, and complex multi-week scheduling is already in your DNA. Theranostics is an extension of your operating model, not a new one.
Diversifying beyond the vault.
Traditional radiation therapy is a high-CAPEX, high-volume game. Radiopharmaceuticals offer a different economic profile. Isotopes are expensive and the marginal cost per dose is real, but the upfront equipment cost for an infusion suite is a fraction of a new LINAC.
The result is a second growth curve sitting on top of the one you already operate. The vault throughput problem stops being the only ceiling on the practice.
Theranostics loop
See it · Treat it
Capturing the growth.
To turn radiopharmaceuticals into a growth engine, your practice has to master the integration of imaging and therapy. That is the core of the theranostics model.
Imaging integration
Use PET/CT to identify the target, for example PSMA for prostate cancer, then use the same ligand to deliver the therapeutic isotope, for example Lutetium-177.
Referral strategy
Position your clinic as a high-acuity center. Focus on patients who have failed standard external beam therapy, or whose metastatic disease is unreachable by traditional means.
Logistics management
RPT growth is a logistics challenge. You have to build a just-in-time supply chain for isotopes with short half-lives, with precise scheduling and a robust shipping log.
2026 outlook, side by side.
| Feature | External beam (EBRT) | Radiopharmaceuticals (RPT) |
|---|---|---|
| Growth ceiling | Limited by vault capacity | Scalable with infusion chairs |
| Capital intensity | Very high (millions) | Moderate (hot lab / PET) |
| Patient reach | Local (30 to 50 miles) | Regional (destination therapy) |
| Marginal cost | Low (electricity / staff) | High (isotope cost) |
| Regulatory burden | Established | High (NRC / agreement state) |
Revenue per patient encounter
Illustrative · USD
The PET-LINAC and beyond.
The next five years will favor practices that can offer a hybrid approach. External beam for local control. Systemic RPT for micrometastatic disease the LINAC simply cannot chase. That combination is the ultimate oncology value proposition.
Practices that integrate these workflows today will be the ones that command the highest valuations in the 2027 buyout market. External beam built the last era of radiation oncology. The targeted ligand will define the next.
A note on the numbers
Reimbursement and cost figures are operator-grade benchmarks drawn from public CMS data, vendor disclosures, and our own advisory work. They are intended to frame the conversation, not replace a transaction-specific underwriting model. Actual numbers vary materially by payer mix, geography, isotope supplier, and case acuity.